TickerHumNYSE · Healthcare · Healthcare Plans
Humana Inc. (HUM)
As of Nov 11, 3:59 PM ET, Humana (HUM) last traded at $446.59, up 1.95% on the day. Its TickerHum research score is 58/100 (average). It reported revenue of $154.19B for the twelve months ending 2026-09-30, up 22.0% year over year, with a 1.5% operating margin.
Ratings
- Valuation: 71/100 — Strongest input: price / sales (ttm) 0.3x. Weakest: price / earnings (ttm) 43.6x.
- Growth: 53/100 — Strongest input: revenue growth (ttm, yoy) +22.0 %. Weakest: diluted eps growth (ttm, yoy) -4.1 %.
- Profitability: 29/100 — Strongest input: return on equity 6.6 %. Weakest: operating margin 1.5 %.
- Financial health: 55/100 — Strongest input: long-term debt / equity 0.61. Weakest: cash / long-term debt 0.60.
- Momentum: 95/100 — Strongest input: 6-month return +46.5 %. Weakest: 3-month return +16.0 %.
- Attention: 72/100 — Strongest input: headlines in the last 7 days 71. Weakest: volume vs 3-month average 1.6x.
- Risk resilience: 42/100 — Strongest input: annualised volatility (1y) 47.0 %. Weakest: max drawdown (1y) -42.4 %.
- Data confidence: 98/100 — Strongest input: quote age (hours) 0 h. Weakest: inputs available 95 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $154.19B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 22.0% | TTM ending 2026-09-30 · 10-Q |
| Net income | $1.25B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $10.25 | TTM ending 2026-09-30 · 10-Q |
| Operating margin | 1.5% | TTM ending 2026-09-30 · 10-Q |
| Net margin | 0.8% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $3.14B | TTM ending 2026-09-30 · 10-Q |
| Cash | $6.94B | as of 2026-09-30 · 10-Q |
| Long-term debt | $11.56B | as of 2026-09-30 · 10-Q |
| Debt / equity | 0.61 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000049071).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.